PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Dosulepin hydrochloride - Pain (Neuropathic)
PAD Profile : Dosulepin hydrochloride - Pain (Neuropathic)
Keywords :
Dothiepin, tricyclic antidepressants, tricyclics, TCAs
Brand Names Include :
Prothiaden
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Duloxetine hydrochloride
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Nortriptyline
- Imipramine hydrochloride
- Tramadol hydrochloride
- Capsaicin
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Policy Statement
01 June 2025
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
02 November 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend the use of ‘off label’ dosulepin for the treatment of neuropathic pain.
See locally agreed neuropathic pain guidelines below
Associated BNF Codes
04. Central Nervous System
04.07.03. Neuropathic pain